Is Arovella Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Arovella Therapeutics Ltd (ALA.AX) is currently classified as NOT HALAL as of October 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Arovella Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Arovella Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Arovella Therapeutics Ltd?

Muslim investors may consider investing in Arovella Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Arovella Therapeutics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Arovella Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Arovella Therapeutics Ltd updated?

The Shariah compliance status of Arovella Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Arovella Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Arovella Therapeutics Ltd?

You can check the latest Shariah compliance status of Arovella Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ALA.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: October 20, 2025

Report Source: 2025 Annual Report

Arovella Therapeutics Ltd. Stock Analysis ALA.AX

Australia Health Care Micro Cap Report: 2025 Annual

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. The firm is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. The company is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. The company focuses on integrating IL-12-TM technology into its solid tumor programs.

Key Statistics of Arovella Therapeutics Ltd (ALA.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.07AUD0.08

Today's Open

AUD0.08

Volume

448.98K

P/E Ratio (TTM)

52 Week Range

AUD0.07AUD0.13

Market Cap

84.61M

Avg. Volume

380.29K

Dividend Yield

Financial Metrics & Statements of Arovella Therapeutics Ltd (ALA.AX)

FAQ's for Arovella Therapeutics Ltd (ALA.AX)

According to Musaffa’s Shariah screening methodology, Arovella Therapeutics Ltd (ALA.AX) is currently classified as NOT HALAL as of October 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.